Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down Syndrome

Neurobiology of Disease

Volumn 63, Issue , 2014, Pages 12-19

  Begenisic, Tatjana ^a   Baroncelli, Laura ^a   Sansevero, Gabriele ^a   Milanese, Marco ^b   Bonifacino, Tiziana ^b   Bonanno, Giambattista ^b   Cioni, Giovanni ^c   Maffei, Lamberto ^a   Sale, Alessandro ^a  

^a CNR   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

Author keywords

Down syndrome; Fluoxetine; GABA; Intellectual disability; Ts65Dn mice

Indexed keywords

FLUOXETINE;

4 AMINOBUTYRIC ACID RELEASE; ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EXPERIMENTAL CONVULSION; FEMALE; HIPPOCAMPUS; LONG TERM CARE; MALE; MEMORY CONSOLIDATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; ORIENTING RESPONSE; PRIORITY JOURNAL; SPATIAL MEMORY; STIMULUS RESPONSE; TASK PERFORMANCE; WORKING MEMORY;

DOWN SYNDROME; FLUOXETINE; GABA; INTELLECTUAL DISABILITY; TS65DN MICE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOPHYSICS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ELECTRIC STIMULATION; FLUOXETINE; GAMMA-AMINOBUTYRIC ACID; HIPPOCAMPUS; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; RECOGNITION (PSYCHOLOGY); SPACE PERCEPTION; SYNAPTOSOMES;

EID: 84890284361     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.11.010     Document Type: Article

References (63)

1. Baroncelli L., et al. Experience-dependent reactivation of ocular dominance plasticity in the adult visual cortex. Exp. Neurol. 2010, 226:100-109.
2. Baroncelli L., et al. Brain plasticity and disease: a matter of inhibition. Neural Plast. 2011, 2011:286073.
3. Bartesaghi R., et al. Is it possible to improve neurodevelopmental abnormalities in Down syndrome?. Rev. Neurosci. 2011, 22:419-455.
4. Begenisic T., et al. Environmental enrichment decreases GABAergic inhibition and improves cognitive abilities, synaptic plasticity, and visual functions in a mouse model of Down syndrome. Front. Cell. Neurosci. 2011, 5:29.
5. Belichenko P.V., et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. J. Comp. Neurol. 2009, 512:453-466.
6. Best T.K., et al. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J. Neurophysiol. 2007, 97:892-900.
7. Bevins R.A., Besheer J. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory'. Nat. Protoc. 2006, 1:1306-1311.
8. Bianchi P., et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
9. Bimonte-Nelson H.A., et al. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav. Brain Res. 2003, 139:47-57.
10. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection. Mol. Neurobiol. 2004, 29:289-302.
11. Clark S., et al. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Exp. Neurol. 2006, 200:256-261.
12. Colas D., et al. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. Br. J. Pharmacol. 2013, 169:963-973.
13. Costa A.C., Grybko M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci. Lett. 2005, 382:317-322.
14. Costa A.C., et al. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008, 33:1624-1632.
15. Costa A.C., et al. Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behav. Brain Res. 2010, 206:52-62.
16. Davisson M.T., et al. Segmental trisomy as a mouse model for Down syndrome. Prog. Clin. Biol. Res. 1993, 384:117-133.
17. Demas G.E., et al. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav. Brain Res. 1996, 82:85-92.
18. Dierssen M. Down syndrome: the brain in trisomic mode. Nat. Rev. Neurosci. 2012, 13:844-858.
19. Dierssen M., et al. Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res. 1997, 749:238-244.
20. Escorihuela R.M., et al. A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci. Lett. 1995, 199:143-146.
21. Faizi M., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol. Dis. 2011, 43:397-413.
22. Fernandez F., Garner C.C. Over-inhibition: a model for developmental intellectual disability. Trends Neurosci. 2007, 30:497-503.
23. Fernandez F., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat. Neurosci. 2007, 10:411-413.
24. Gardiner K., et al. Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003, 318:137-147.
25. Guidi S., et al. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Brain Pathol. 2012, 23:129-143.
26. Hajszan T., et al. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur. J. Neurosci. 2005, 21:1299-1303.
27. Heinen M., et al. Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast. 2012, 2012:467251.
28. Karpova N.N., et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 2011, 334:1731-1734.
29. Kleschevnikov A.M., et al. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J. Neurosci. 2004, 24:8153-8160.
30. Kleschevnikov A.M., et al. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol. Dis. 2012, 45:683-691.
31. Koyama S., et al. Presynaptic serotonergic inhibition of GABAergic synaptic transmission in mechanically dissociated rat basolateral amygdala neurons. J. Physiol. 1999, 518(Pt 2):525-538.
32. Li I.H., et al. Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET. Neuroimage 2009, 49:1259-1270.
33. Malberg J.E., et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 2000, 20:9104-9110.
34. Martinez-Cue C., et al. Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J. Neurosci. 2013, 33:3953-3966.
35. Maya Vetencourt J.F., et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 2008, 320:385-388.
36. Mendez P., et al. Direct alteration of a specific inhibitory circuit of the hippocampus by antidepressants. J. Neurosci. 2012, 32:16616-16628.
37. Milanese M., et al. Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 2011, 116:1028-1042.
38. Moore C.S., Roper R.J. The power of comparative and developmental studies for mouse models of Down syndrome. Mamm. Genome 2007, 18:431-443.
39. Mumby D.G., et al. Hippocampal damage and exploratory preferences in rats: memory for objects, places, and contexts. Learn. Mem. 2002, 9:49-57.
40. Nadel L. Down's syndrome: a genetic disorder in biobehavioral perspective. Genes Brain Behav. 2003, 2:156-166.
41. Oke A., et al. Dose-dependent seizure activity associated with fluoxetine therapy. QJM 2001, 94:113-114.
42. Pennington B.F., et al. The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev. 2003, 74:75-93.
43. Perez-Cremades D., et al. Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J. Neural Transm. 2010, 117:445-455.
44. Perry K.W., Fuller R.W. Fluoxetine increases norepinephrine release in rat hypothalamus as measured by tissue levels of MHPG-SO4 and microdialysis in conscious rats. J. Neural Transm. 1997, 104:953-966.
45. Pollonini G., et al. Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn. Neuroscience 2008, 156:99-106.
46. Raiteri M., et al. Is there a functional linkage between neurotransmitter uptake mechanisms and presynaptic receptors?. J. Pharmacol. Exp. Ther. 1984, 231:671-677.
47. Raju S.S., et al. Effect of fluoxetine on maximal electroshock seizures in mice: acute vs chronic administration. Pharmacol. Res. 1999, 39:451-454.
48. Rantamaki T., et al. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology 2007, 32:2152-2162.
49. Reeves R.H., et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
50. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
51. Rosenstein D.L., et al. Seizures associated with antidepressants: a review. J. Clin. Psychiatry 1993, 54:289-299.
52. Rueda N., et al. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci. Lett. 2008, 433:22-27.
53. Sale A., et al. Environmental enrichment in adulthood promotes amblyopia recovery through a reduction of intracortical inhibition. Nat. Neurosci. 2007, 10:679-681.
54. Seregaza Z., et al. Mouse models of cognitive disorders in trisomy 21: a review. Behav. Genet. 2006, 36:387-404.
55. Siarey R.J., et al. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology 1997, 36:1549-1554.
56. Siarey R.J., et al. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 1999, 38:1917-1920.
57. Silva A.J., Ehninger D. Adult reversal of cognitive phenotypes in neurodevelopmental disorders. J. Neurodev. Disord. 2009, 1:150-157.
58. Stagni F., et al. Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome. PLoS One 2013, 8:e61689.
59. Suchard J.R. Fluoxetine overdose-induced seizure. West. J. Emerg. Med. 2008, 9:154-156.
60. Wang C., Zucker R.S. Regulation of synaptic vesicle recycling by calcium and serotonin. Neuron 1998, 21:155-167.
61. Westmark C.J., et al. Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures. J. Alzheimers Dis. 2010, 20:1009-1013.
62. Xiang Z., Prince D.A. Heterogeneous actions of serotonin on interneurons in rat visual cortex. J. Neurophysiol. 2003, 89:1278-1287.
63. Zienowicz M., et al. The effect of fluoxetine in a model of chemically induced seizures-behavioral and immunocytochemical study. Neurosci. Lett. 2005, 373:226-231.